Full-Time

Associate Director

HCP Marketing, Alzheimer's Disease Agitation

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for central nervous system disorders

Biotechnology
Healthcare

Compensation Overview

$160k - $190kAnnually

+ Annual Bonus + Equity

Senior, Expert

New York, NY, USA

On-site requirement of at least three days per week.

Category
General Marketing
PR & Communications
Growth & Marketing
Required Skills
Branding/Brand Strategy

You match the following Axsome Therapeutics Inc's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • BA or BS, advanced degree preferred
  • 8-10 years of experience in the pharmaceutical industry including a minimum of 6 years in marketing
  • HCP Marketing experience
  • Launch experience strongly preferred
  • Strong personal drive, highly collaborative, problem solver that exhibits strategic insight and innovative agility
  • Ability to meet multiple deadlines across a variety of projects with a high degree of accuracy and efficiency
  • Demonstrated ability to achieve results in a highly matrixed organization
  • Ability to work on site Monday, Tuesday & Thursday. We are unable to consider candidates looking for fully remote roles.
Responsibilities
  • Lead development and execution of HCP material content ensuring KOL input into the development of all material
  • Work cross-functionally to develop a comprehensive peer-to-peer strategy for AXS-05
  • Build a diverse, experienced speakers bureau for AXS-05 including identification, contracting and training of KOLs
  • Partner with Training and Marketing Operations to develop and execute a comprehensive training program
  • Lead Legal / Regulatory / Medical review of HCP materials
  • Lead all advisory board meetings for AXS-05 in preparation for launch and develop a structured format to gain continuous insight from KOLs post-launch
  • Identify strategic market opportunities and make recommendations to enhance brand strategy
  • Manage timelines and budgets in accordance with brand plan
Desired Qualifications
  • Demonstrated proactive, creative and entrepreneurial approach
  • CNS disease experience
  • Strong project and process management skills, including competency in agency management and budget management
  • Strong marketing aptitude
  • Strong interpersonal and presentation skills
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, allowing for faster development. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
  • Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
  • Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

What critics are saying

  • Increased competition from companies like Compass Pathways in the CNS market.
  • Potential delays in AXS-07 launch amid growing market anticipation.
  • Departure of key personnel like Lori Englebert may impact strategic direction.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders with limited current treatment options.
  • AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity